SUO 2017: Optimal Management of Castrate Sensitive M1 PCA
Washington, DC (UroToday.com) Dr. Kim Chi provided a comprehensive review of the optimal management of castrate sensitive M1 prostate cancer. Dr. Chi notes that in the past few years we have had several practice-changing trials in the metastatic castrate sensitive setting, including the addition of docetaxel [1,2] and abiraterone [3,4] to ADT.
SUO 2017: Does Time From Diagnosis To Treatment Of Very High Or High Risk Prostate Cancer Affect
Washington, DC (UroToday.com) Introduction: Limited data exist on the effect of time from diagnosis to treatment in high or very high risk (VHR) prostate cancer (PCa). The relevance of this issue beyond logistics and access to care is increasing with the advent of many neoadjuvant treatment protocols which may inherently delay local therapy. IN this study the authors examined whether time from diagnosis to treatment impacted outcomes in a large multi-institutional cohort of high and VHR PCa patients undergoing radical prostatectomy (RP).
SUO 2017: Novel Targeted Androgen Ablation Prior to Radical Prostatectomy
Washington, DC (UroToday.com) Dr. Kibel from the Dana-Farber Cancer Institute discussed novel targeted androgen ablation prior to radical prostatectomy. Dr. Kibel commenced his presentation by noting that prostate cancer mortality for Gleason 8-10 disease treated with radical prostatectomy is high, providing clinical equipoise for assessing neoadjuvant options for perhaps improving outcomes in these at-risk patients.
SUO 2017: Do African American Men Have A Higher Rate Of Discontinuation On Active Surveillance?
Washington, DC (UroToday.com) Introduction: In this study the authors aimed to compare the discontinuation rates of African American (AA) men with Prostate Cancer (PCa) on Active Surveillance (AS) to age and Gleason matched controls.
SUO 2017: Rates And Risk Factors Of Lost To Follow Up In Prostate Cancer Patients Managed With Active Surveillance
Washington, DC (UroToday.com) Introduction: Active surveillance (AS) has emerged as an appropriate management strategy for many men with prostate cancer (PC), however insufficient monitoring may lead to an increased risk of undesired outcomes. The authors therefore evaluated a large AS cohort across diverse practices in Michigan to determine rates of loss to follow-up (LTFU) and associated risk factors.
SUO 2017: Management of Recurrent Disease in the Current Era of Kidney Cancer Management
Washington, DC (UroToday.com) Dr. Paul Russo from Memorial Sloan Kettering Cancer Center presented the management of recurrent disease in the current era of kidney cancer management. Dr. Russo notes that in the era of minimally invasive surgery, there can be unusual patterns of recurrence with different GU cancers. For instance, he has seen cases of robotic cystectomy for low grade Ta urothelial carcinoma in which the patient developed and ultimately died of carcinomatosis, a laparoscopic RPLND for NSGCT in which the patient developed carcinomatosis, as well as similar cases for patients with adrenal cortical carcinoma and seminal vesicle sarcoma treated with minimally invasive modalities. As Dr. Russo mentions, this is not a new phenomenon, considering there are reports going back to the early days of laparoscopy, as well as contemporary studies documenting port site metastatic disease1.
SUO 2017: Leveraging Salvage Prostatectomy Specimens To Develop Novel Biomarkers Of Radiation Resistance
Washington, DC (UroToday.com) Introduction: Primary radiation therapy (RT) has a relatively high rate of biochemical recurrence of 30-50% in intermediate and high-risk prostate cancer (PC). While recurrence may be a function of advanced disease at the time of RT, the finding of viable radioresistant PC in salvage prostatectomy specimens suggests that some PCs may be intrinsically resistant to RT, according to the authors of this study.